RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
Status:
Not yet recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
This study is testing the way that approved androgen deprivation therapy treatments,
Leuprolide and Relugolix, for prostate cancer affect quality of life, blood levels,
cholesterol, and blood sugar. The drugs are already standard treatment for people with
prostate cancer, and the drugs will be used as described in their label.
The names of the study drugs involved in this study are:
- Leuprolide (type of ADT)
- Relugolix (type of ADT)
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Myovant Sciences GmbH Pfizer Prostate Cancer Foundation